Morgan Stanley's price target for the hardware company currently stands at $129. This implies that shares of Seagate could rise 25% in order to reach that level. Seagate is a leading manufacturer of ...

Morgan Stanley (NYSE:MS) updated its outlook on KLA Corporation (NASDAQ:KLAC), increasing its price target to $748 from the previous target of $703, while the firm's rating for the stock remains at ...

We recently compiled a list of the 12 AI News Investors Probably Missed. In this article, we are going to take a look at ...

Morgan Stanley (NYSE:MS) analyst Joseph Moore revised the price target for Teradyne stock (NASDAQ:TER), dropping it to $112 from the previous $117, while maintaining an Underweight rating on the ...

Morgan Stanley (MS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Financial giants have made a conspicuous bullish move on Morgan Stanley. Our analysis of options history for Morgan Stanley (NYSE:MS) revealed 8 unusual trades. Delving into the details ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Morgan Stanley. Looking at options history for Morgan Stanley (NYSE:MS) we detected 24 trades. If we consider the ...

Morgan Stanley (NYSE:MS) analysts, led by Keith Weiss, adjusted the price target for Microsoft (NASDAQ:MSFT) shares, reducing ...

We recently compiled a list of the 10 AI Stocks to Watch Amid the DeepSeek Buzz. In this article, we are going to take a look ...

Morgan Stanley (NYSE:MS) reaffirmed its confidence in Tesla stock (NASDAQ:TSLA), maintaining an Overweight rating with a steady price target of $430.00. The firm's analysis suggests Tesla is evolving ...

Broadcom Inc. (NASDAQ:AVGO – Get Free Report) fell 0.8% during mid-day trading on Tuesday after Morgan Stanley lowered their price target on the stock from $265.00 to $246.00. Morgan Stanley currently ...

Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ziclumeran ...